ArticleBiomedical reports2016
Mass spectrometric signatures of the blood plasma metabolome for disease diagnostics.
Article in Biomedical reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- CXCL10 promotes non-small cell lung cancer (NSCLC) progression by modulating the phosphate to urate ratio (PUR).Discover oncology · 2025Article
- Integrating Rapid Evaporative Ionization Mass Spectrometry Classification with Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging and Liquid Chromatography-Tandem Mass Spectrometry to Unveil Glioblastoma Overall Survival Prediction.ACS chemical neuroscience · 2025Article
- Transcutaneous intravascular laser irradiation of blood affects plasma metabolites of women.Scientific reports · 2024Article
- Acoustically targeted measurement of transgene expression in the brain.Science advances · 2024Article
- New insights into healthy ageing, inflammageing and frailty using metabolomics.Frontiers in aging · 2024Review
- Causal role of metabolites in non-small cell lung cancer: Mendelian randomization (MR) study.PloS one · 2024Article
- Metabolomic Profiling of Peripheral Plasma by GC-MS and Correlation With Size of Uterine Leiomyomas.Journal of the Endocrine Society · 2022Article
- Holistic Metabolomic Laboratory-Developed Test (LDT): Development and Use for the Diagnosis of Early-Stage Parkinson's Disease.Metabolites · 2020Article
- In Situ Mass Spectrometry Diagnostics of Impaired Glucose Tolerance Using Label-Free Metabolomic Signature.Diagnostics (Basel, Switzerland) · 2020Article
- Metabolomics Community in Russia: History of Development, Key Participants, and Results.Biotech (Basel (Switzerland)) · 2020Review
- Parkinson's Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization.Diagnostics (Basel, Switzerland) · 2020Review
- Diagnosis of Parkinson's Disease by A Metabolomics-Based Laboratory-Developed Test (LDT).Diagnostics (Basel, Switzerland) · 2020Article
- A Metabolomics Approach to Pharmacotherapy Personalization.Journal of personalized medicine · 2018Review
- Prostate cancer diagnosis and characterization with mass spectrometry imaging.Prostate cancer and prostatic diseases · 2018Review
- Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.Lung cancer (Amsterdam, Netherlands) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In metabolomics, a large number of small molecules can be detected in a single run. However, metabolomic data do not include the absolute concentrations of each metabolite. Generally, mass spectrometry analyses provide metabolite concentrations that are derived from mass peak intensities, and the peak intensities are strictly dependent on the type of mass spectrometer used, as well as the technical characteristics, options and protocols applied. To convert mass peak intensities to actual concentrations, calibration curves have to be generated for each metabolite, and this represents a significant challenge depending on the number of metabolites that are detected and involved in metabolome-based diagnostics. To overcome this limitation, and to facilitate the development of diagnostic tests based on metabolomics, mass peak intensities may be expressed in quintiles. The present study demonstrates the advantage of this approach. The examples of diagnostic signatures, which were designed in accordance to this approach, are provided for lung and prostate cancer (leading causes of mortality due to cancer in developed countries) and impaired glucose tolerance (which precedes type 2 diabetes, the most common endocrinology disease worldwide).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.